

Special Issue

Advances in Hydrazone Compounds with Anticancer Activity

Message from the Guest Editors

Hydrazones, characterized by their $R-C=N-NH-R'$ linkage, are attracting widespread attention in medicinal chemistry as a promising class of anticancer agents. One important trend in this domain is the development of novel hydrazone derivatives with enhanced potency and selectivity, with structural modifications—such as the incorporation of heterocyclic rings, introduction of halogen atoms, and optimization of substituent groups, including methoxy, methyl, and amino groups—serving as strategies. Another means by which to increase activity is to include hydrazones as ligands in various metal complexes. The conjugation of hydrazones with nanoparticles is also being examined to ensure the precise targeting of the tumor while minimizing systemic toxicity and maximizing therapeutic concentration at target sites.

This Special Issue focuses on advances in the design, synthesis, and anticancer activity of novel hydrazones and their metal complexes. Authors are encouraged to contribute original research articles, reviews, and short communications examining hydrazones that selectively target specific cancer hallmarks, leading to improved efficacy and reduced off-target effects.

Guest Editors

Dr. Boryana Nikolova-Mladenova

Faculty of Pharmacy, Medical University of Sofia, 1000 Sofia, Bulgaria

Prof. Dr. Mariyana Atanasova

Faculty of Pharmacy, Medical University of Sofia, 1000 Sofia, Bulgaria

Deadline for manuscript submissions

25 November 2025



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/239793

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)